Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises SBB on its offer for Hemfosa
Mandate

Vinge advises SBB on its offer for Hemfosa

November 15, 2019 Capital Markets and Public M&A

Samhällsbyggnadsbolaget i Norden AB (publ) (“SBB”) has announced a recommended public offer to the shareholders of Hemfosa Fastigheter AB (publ) (“Hemfosa”) to tender all their shares in Hemfosa to SBB.

The total offer consideration consists of a combination of cash and SBB shares. At announcement, the total offer value for all Hemfosa shares is approximately SEK 23.5 billion. SBB is a major Nordic social infrastructure property company with a property portfolio with a market value of SEK 30.8 billion as of 30 September 2019. SBB’s Class B and Class D common shares are listed in Nasdaq Stockholm, Large Cap.

SBB has retained Vinge as legal advisor. The Vinge team mainly consist of Jesper Schönbeck, Erik Sjöman, Rikard Lindahl, Malte Hedlund, Boris Kotur and Clara Sohlberg, and Albert Wållgren, Ludvig Wettergren and Axel Jansson (on finance matters), Trine Osen Bergqvist and Johan Wahlbom (on competition matters) and Maria Schultzberg and Victor Ericsson (on tax matters).

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025